DDInter596 DDInter1641
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) upregulates {v} (Gene) GPC1
GPC1 {u} (Gene) is upregulated by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) downregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) downregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline